| Literature DB >> 26597827 |
Ken-Ichiro Tanaka1, Ippei Kanazawa2, Hitomi Miyake1, Shozo Yano3, Chika Amano4, Noriyoshi Ishikawa5, Riruke Maruyama5,6, Toshitsugu Sugimoto1.
Abstract
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder, which represents various symptoms caused by the hyperproduction of interleukin-6 (IL-6). However, case studies of MCD accompanied by hypercalcemia have rarely been reported thus far. A 78-year-old male had generalized fatigue, and his laboratory data revealed elevated serum calcium (Ca) and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels (11.5 mg/dl and 80 pg/ml, respectively), while the serum intact parathyroid hormone level was low (4 pg/ml). Computed tomography showed multicentric lymphadenopathy. The serum IL-6 level was elevated (20.7 pg/ml), and pathological examination of a supraclavicular lymph node specimen led us to diagnose MCD. Moreover, immunostaining analysis showed that vitamin D-activating enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase was expressed in lymph node macrophages. Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6. We first reported a case of vitamin D-mediated hypercalcemia in MCD.Entities:
Keywords: 25-Hydroxyvitamin D 1-alpha-hydroxylase; Castleman disease; Hypercalcemia; Prednisolone; Vitamin D
Mesh:
Substances:
Year: 2015 PMID: 26597827 DOI: 10.1007/s00774-015-0726-7
Source DB: PubMed Journal: J Bone Miner Metab ISSN: 0914-8779 Impact factor: 2.626